TELA

TELA Bio, Inc.

TELA | $5.15 -0.39% -0.39% 95K

(0.0% 1d) (-6.2% 1m) (-44.2% 1y) (0.0% 2d) (0.0% 3d) (10.0% 7d) (-90.62% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 126,945,414
http://www.telabio.com
Sec Filling | Patents | 89 employees

TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.

education

add to watch list Paper trade email alert is off

Press-releases

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| 5.08% | O: 1.63% H: 1.0% C: -6.0%
ovitex natural for commercial

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| -0.77% | O: -3.26% H: 6.35% C: 2.38%
medical

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
Published: 2024-03-21 (Crawled : 20:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| -3.36% | O: 4.49% H: 8.23% C: 2.5%
year financial results

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Published: 2024-03-21 (Crawled : 11:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| -6.17% | O: -0.91% H: 9.52% C: -2.01%
commercial

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| -3.36% | O: 2.8% H: 1.09% C: 0.18%
MDXG | $6.17 -2.53% -2.59% 540K

Health Technology

| -21.37% | O: -0.62% H: 2.75% C: 2.5%

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| -3.36% | O: 2.8% H: 1.09% C: 0.18%
MDXG | $6.17 -2.53% -2.59% 540K

Health Technology

| -21.37% | O: -0.62% H: 2.75% C: 2.5%
distribution care

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-29 (Crawled : 12:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| -23.41% | O: 1.93% H: 0.0% C: -1.74%
year financial results

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-23 (Crawled : 21:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| Email alert Add to watchlist
nasdaq grants

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-19 (Crawled : 21:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| Email alert Add to watchlist
nasdaq grants

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-15 (Crawled : 21:00) - globenewswire.com
TELA | $5.15 -0.39% -0.39% 95K

Health Technology

| Email alert Add to watchlist
nasdaq grants

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001062993-24-007843	4	2024-04-02	2024-03-31	Sell	F	119	50627
0001062993-24-007842	4	2024-04-02	2024-03-31	Sell	F	385	370009
0001062993-24-007841	4	2024-04-02	2024-03-31	Sell	F	190	68860
0001062993-24-007840	4	2024-04-02	2024-03-31	Sell	F	96	29000